Author Archives for Lea Scheppke

Neurotech Receives Priority Review of Biologics License Application for NT-501 as a Treatment for Macular Telangiectasia Type 2

June 27, 2024 9:15 am Published by Lea Scheppke

June 20, 2024 LMRI would like to share the news that Neurotech has received Priority Review of Biologics License Application... View Article

What To Expect in a MacTel Imaging Exam

May 2, 2024 2:51 pm Published by Lea Scheppke

April 29, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.  ... View Article

MacTel SAFE Study

March 7, 2024 11:30 am Published by Lea Scheppke

March 6, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.  ... View Article

MacTel Project 2023 Annual Meeting Summary

February 6, 2024 6:47 pm Published by Lea Scheppke

February 6, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.  ... View Article

Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Macular Telangiectasia Type 2 (MacTel) Patients with and without Diabetes

May 29, 2023 5:49 pm Published by Lea Scheppke

Lydia Sauer, Alexandra S Vitale, Rachael S Jacoby, Barbara Hart, Paul S Bernstein.  Retina.  2023 May 29.  doi: 10.1097/IAE.0000000000003851.

iPSC-derived retinal pigmented epithelial cells from patients with macular telangiectasia show decreased mitochondrial function

May 10, 2023 4:58 pm Published by Lea Scheppke

Eade KT, Ansell BRE, Giles S, Fallon R, Harkins-Perry S, Nagasaki T, Tzaridis S, Wallace M, Mills EA, Farashi S,... View Article

Macular Telangiectasia Type 2: A Classification System Using Mulit-Modal Imaging MacTel Project Report Number 10

December 14, 2022 10:00 am Published by Lea Scheppke

Emily Y. Chew, Tunde Peto, Traci E. Clemons, Ferenc B. Sallo, Daniel Pauleikhoff, Irene Leung, Glenn J. Jaffe, Tjebo F.C.... View Article

Positive Phase 3 Topline Results Announced for NT-501 Implant in MacTel

November 2, 2022 12:48 pm Published by Lea Scheppke

November 2, 2022 Neurotech Pharmaceuticals, Inc. announces positive Phase 3 topline results for NT-501 implant in macular telangiectaisa type 2... View Article

Description of a patient cohort with Hereditary Sensory Neuropathy Type 1 without retinal disease Macular Telangiectasia type 2 – implications for retinal screening in HSN1

July 20, 2022 3:48 pm Published by Lea Scheppke

Filipa Gomes Rodrigues, Menelaos Pipis, Tjebo F C Heeren, Marcus Fruttiger, Mari Gantner, Sandra Vermeirsch, Mali Okada, Martin Friedlander, Mary M Reilly, Catherine Egan.  J Peripher Nerv Syst. 2022... View Article

Cell-specific cis-regulatory elements and mechanisms of non-coding genetic disease in human retina and retinal organoids

March 28, 2022 10:45 am Published by Lea Scheppke

Eric D Thomas, Andrew E Timms, Sarah Giles, Sarah Harkins-Perry, Pin Lyu, Thanh Hoang, Jiang Qian, Victoria E Jackson, Melanie Bahlo, Seth Blackshaw, Martin Friedlander, Kevin Eade, Timothy J Cherry.  Dev Cell.  2022... View Article